Related Experiment Video
Updated: Mar 28, 2026
06:21
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
1.4K
Association Between NAT2 Polymorphisms and Lung Cancer Susceptibility
1From the Department of Medical Oncology, The Military General Hospital of Beijing PLA, Beijing, China (CL, LW, XR, JJ, YL, XJ, XZ); Department of General Surgery, The Military General Hospital of Beijing PLA, Beijing, China (WC); and Department of Dermatology, The Military General Hospital of Beijing PLA, Beijing, China (LC).
Medicine
|December 15, 2015
Summary
The N-acetyltransferase 2 (NAT2) gene
Area of Science:
- Genetics
- Oncology
- Pharmacogenomics
Background:
- N-acetyltransferase 2 (NAT2) is a key enzyme in drug metabolism.
- NAT2 genetic variations (polymorphisms) influence individual susceptibility to various cancers, including lung cancer.
- Understanding the association between NAT2 polymorphisms and lung cancer risk is crucial for personalized medicine.
Purpose of the Study:
- To conduct a comprehensive meta-analysis investigating the association between NAT2 polymorphisms and lung cancer susceptibility.
- To evaluate both phenotypic (acetylator status) and genotypic (specific single nucleotide polymorphisms) associations.
- To identify specific NAT2 variants that may confer increased lung cancer risk.
Main Methods:
- A systematic literature search was performed across PubMed, Embase, and CNKI databases.
- Twenty-six eligible studies were included in the meta-analysis.
- Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess lung cancer risk associated with NAT2 polymorphisms.
Main Results:
- Phenotypic analysis revealed no significant association between NAT2 acetylator status and lung cancer susceptibility across different ethnicities and control groups.
- Genotypic analysis showed no overall significant relationship between NAT2 polymorphisms and lung cancer risk.
- However, the TT genotype of the NAT2 C282T polymorphism was significantly associated with an increased risk of lung cancer (OR = 1.58, 95% CI = 1.11-2.25).
Conclusions:
- The TT genotype of the NAT2 C282T polymorphism may represent a risk factor for lung cancer.
- NAT2 acetylator status, based on the studied single nucleotide polymorphisms (SNPs), does not appear to be significantly associated with lung cancer risk.
- Further research is warranted to elucidate the precise role of specific NAT2 genotypes in lung carcinogenesis.
Related Concept Videos
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
61
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
61
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
68
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
109
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
01:05Single Nucleotide Polymorphisms-SNPs
19.8K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.8K
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
116
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
116
01:27Pharmacogenetics of Drug Metabolism: Overview
111
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
111